Listing - September 10, 2020
AstraZeneca to list US ADR equity and all US debt securities on Nasdaq
AstraZeneca has announced that it will be transferring the listing of its American Depositary Receipts (ADRs) and its US listed debt securities from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (Nasdaq) and Nasdaq Bond Exchange respectively. The transfers will be effective after market close on Thursday 24 September 2020. AstraZeneca […]
Pharma Business - September 4, 2020
AstraZeneca’s Imfinzi approved in the EU for the treatment of extensive-stage small cell lung cancer
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin. SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response […]
COVID-19 - September 1, 2020
AstraZeneca issues a commitment for COVID-19 vaccine
AstraZeneca is issuing a commitment to the highest safety standards and to broad and equitable access around the world for its COVID-19 vaccine AZD1222, it states. Follow the science and put patients first At the heart of AstraZeneca’s core values is to “follow the science” and adhere to the highest scientific and clinical standards, making […]
COVID-19 - September 1, 2020
AstraZeneca expands its US COVID-19 vaccine trial
Development of AstraZeneca’s COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups. The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) […]
Clinical Trials - August 31, 2020
New results from AstraZeneca’s Farxiga trial
Detailed results from the Phase III DAPA-CKD trial showed that Farxiga on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo (p<0.0001) in patients with chronic kidney disease (CKD) Stages 2-4 and elevated urinary albumin excretion. The […]
Clinical Trials - August 25, 2020
Cancer clinical trials changes during the COVID-19 pandemic
AstraZeneca’s EVP of Oncology R&D, José Baselga, shares his top five takeaways from the AACR COVID-19 and Cancer virtual meeting. The American Association for Cancer Research (AACR) organized a COVID-19 and Cancer virtual meeting, bringing together voices from across the healthcare continuum to share learnings from this unprecedented time. Baselga served as a panellist for […]
